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Background: The combination of paclitaxel with cisplatin or carboplatin has significant activity in
non-small-cell lung cancer (NSCLC). This phase III study of chemotherapy-naïve advanced NSCLC
patients was designed to assess whether response rate in patients receiving a paclitaxel/carboplatin
combination was similar to that in patients receiving a paclitaxel/cisplatin combination. Paclitaxel was
given at a dose of 200 mg/m2 (3-h intravenous infusion) followed by either carboplatin at an AUC of
6 or cisplatin at a dose of 80 mg/m2, all repeated every 3 weeks. Survival, toxicity and quality of life
were also compared.
Patients and methods: Patients were randomised to receive one of the two combinations, stratified
according to centre, performance status, disease stage and histology. The primary analyses of response
rate and survival were carried out on response-evaluable patients. Survival was also analysed for all
randomised patients. Toxicity analyses were carried out on all treated patients.
Results: A total of 618 patients were randomised. The two treatment arms were well balanced with
regard to gender (83% male), age (median 58 years), performance status (83% ECOG 0–1), stage
(68% IV, 32% IIIB) and histology (38% squamous cell carcinoma). In the paclitaxel/carboplatin arm,
306 patients received a total of 1311 courses (median four courses, range 1–10 courses) while in the
paclitaxel/cisplatin arm, 302 patients received a total of 1321 courses (median four courses, range 1–10
courses). In only 76% of courses, carboplatin was administered as planned at an AUC of 6, while in 96%
of courses, cisplatin was given at the planned dose of 80 mg/m2. The response rate was 25% (70 of 279)
in the paclitaxel/carboplatin arm and 28% (80 of 284) in the paclitaxel/cisplatin arm (P = 0.45).
Responses were reviewed by an independent radiological committee. For all randomised patients,
median survival was 8.5 months in the paclitaxel/carboplatin arm and 9.8 months in the paclitaxel/
cisplatin arm [hazard ratio 1.20, 90% confidence interval (CI) 1.03–1.40]; the 1-year survival rates were
33% and 38%, respectively. On the same dataset, a survival update after 22 months of additional follow-
up yielded a median survival of 8.2 months in the paclitaxel/carboplatin arm and 9.8 months in the
paclitaxel/cisplatin arm (hazard ratio 1.22, 90% CI 1.06–1.40; P = 0.019); the 2-year survival rates were
9% and 15%, respectively. Excluding neutropenia and thrombocytopenia, which were more frequent in
the paclitaxel/carboplatin arm, and nausea/vomiting and nephrotoxicity, which were more frequent in
the paclitaxel/cisplatin arm, the rate of severe toxicities was generally low and comparable between the
two arms. Overall quality of life (EORTC QLQ-C30 and LC-13) was also similar between the two arms.
Conclusions: This is the first trial comparing carboplatin and cisplatin in the treatment of advanced
NSCLC. Although paclitaxel/carboplatin yielded a similar response rate, the significantly longer
median survival obtained with paclitaxel/cisplatin indicates that cisplatin-based chemotherapy should
be the first treatment option.
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Introduction
Cisplatin is still the backbone of chemotherapy combinations
in non-small-cell lung cancer (NSCLC), and several combina-
tions of cisplatin-based chemotherapy are used in the current
treatment of this disease. While carboplatin has also been used
extensively, especially in the USA in combination with pacli-
taxel, to date no randomised trial has compared these two
drugs at the same dose schedule. A previous trial [1] by the
European Organization for Research and Treatment of Cancer
(EORTC) combining VP16 with cisplatin (120 mg/m2) or
carboplatin (325 mg/m2) yielded a slightly higher but not
significant difference in response rate and survival in favour
of the cisplatin combination; however, renal function impair-
ment and myelotoxicity were significantly higher in the
cisplatin arm.
There is ample evidence that cisplatin has a pivotal role in
NSCLC management [2]. In the meta-analysis undertaken by
the Non-Small-Cell Lung Cancer Collaborative Group, a
hazard ratio of 0.73 was observed (27% reduction in the risk of
death and 10% improvement in survival at 1 year) when cis-
platin chemotherapy was compared with best supportive care
[3]. A later British study was also able to confirm the benefit
of cisplatin-based chemotherapy [4]. A North American meta-
analysis found that only five of 33 (15%) phase III studies
showed significant differences in survival in favour of the
patient cohort receiving the experimental therapy. Four of these
five trials included cisplatin-based regimens [5]. Vinorelbine
as a single agent was the first non-cisplatin drug to show a
survival advantage, with median survival of 30 weeks, com-
pared with 22 weeks for those who were treated with fluoro-
uracil plus leucovorin [6].
Intriguingly, paclitaxel as a single agent showed a median
survival of 6.8 months, in contrast to 4.8 months for support-
ive care alone. The median time to disease progression was
3.9 months for patients in the paclitaxel arm and 0.5 months
for supportive care alone. The Cox regression model showed a
hazard ratio of 0.68 in favour of paclitaxel. No responses were
observed in patients with poor performance status, which was
more frequent in patients ≥65 years old than in younger
patients [7]. Other studies have also identified older age as a
prognostic factor for response and survival [8–10]. Phase II
studies have demonstrated activity for paclitaxel as a 24-h
intravenous infusion, both as a single agent and in combina-
tion with carboplatin [11–14]. Paclitaxel as a 24-h intravenous
infusion plus cisplatin (75 mg/m2) has been compared with
cisplatin/etoposide. The response rate for paclitaxel/cisplatin
was ∼26%, while that for cisplatin/etoposide was 12.4%
(P <0.001). The median survival time was 9.9 months versus
7.6 months (P = 0.04) [15]. However, an EORTC trial of
cisplatin/teniposide versus cisplatin/paclitaxel (175 mg/m2 as
a 3-h intravenous infusion) found no significant difference in
median survival times (9.9 versus 9.7 months respectively),
although response rate was higher in the paclitaxel arm (28%
versus 41%; P = 0.01) [16]. Single-agent cisplatin (100 mg/m2)
has been compared with paclitaxel (175 mg/m2) plus cisplatin
(80 mg/m2). Although there were differences in response rate
and progression-free survival in favour of the combination
arm, median survival was similar in the two arms (8.6 months
in the cisplatin arm and 8.1 months in the paclitaxel/cisplatin
arm) [2].
Other studies have explored the administration of paclitaxel
given as a 3-h intravenous infusion in combination with carbo-
platin. Median survival was 30 weeks, but rose to 39 weeks
when paclitaxel doses were >175 mg/m2, with carboplatin doses
of 350–400 mg/m2 [17]. Paclitaxel (175 versus 225 mg/m2) as
a 3-h intravenous infusion has been tested in combination with
carboplatin (AUC of 6), with slight differences in favour of
the higher paclitaxel dose in terms of response, progression-
free survival and median survival [18]. A recent trial by the
Southwest Oncology Group (SWOG) epitomised the current
outcomes that are achieved with chemotherapy. Vinorelbine/
cisplatin (100 mg/m2) was compared with paclitaxel given as a
3-h intravenous infusion in combination with carboplatin
(AUC of 6). The response rates were 28% and 25%, respect-
ively, and median survival was the same in both arms
(8 months). However, myelotoxicity and nausea and vomiting
were observed more frequently in the vinorelbine/cisplatin
arm [19]. In a survey of medical oncologists in the USA, the
combination of paclitaxel/carboplatin was the most highly
accepted therapeutic option in NSCLC. This may be explained
by practical considerations, since administration is easier and
toxicity milder than with cisplatin combinations [20].
The present large, randomised, multicentre European trial
tested whether paclitaxel/carboplatin induces a similar benefit
to paclitaxel/cisplatin in terms of objective response rate.
Secondary endpoints were survival, toxicity, quality of life
and the analysis of prognostic factors, including histology.
Paclitaxel (200 mg/m2) was administered in both arms as a 3-h
intravenous infusion with either cisplatin (80 mg/m2) or carbo-
platin (AUC of 6).
Patients and methods
Patients
Eligible patients were required to meet all of the following criteria: (i) a
histological or cytological diagnosis of NSCLC; (ii) stage IIIB (malignant
pleural/pericardial effusions and/or supraclavicular adenopathy) or IV
disease (patients with recurrent stage III or IV disease or restaging after
surgery were eligible); (iii) age 18 years or older; (iv) performance status
of 0, 1 or 2 on the Eastern Cooperative Oncology Group (ECOG) scale
with a predicted life expectancy of at least 12 weeks; (v) measurable (or
non-measurable but assessable) disease, at least one area of which had not
been subject to prior irradiation; (vi) no prior chemotherapy; (vii) any
previous radiation therapy completed >3 weeks before enrolment and
the patient recovered from any adverse effects; (viii) adequate baseline
bone marrow function as documented by an absolute neutrophil count of
1.5 cells × 109/l or higher, platelet count of 100 cells × 109/l or higher,
haemoglobin 9 g/dl or higher; total serum bilirubin level of ≤1.25 times
the upper limit of normal, hepatic transaminase <3 times the upper limit of
normal, and serum creatinine level of ≤1.25 times the upper limit of
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normal. Patients had to be able to understand the EORTC quality-of-life
questionnaire C-30, which had previously been validated in several
language-cultural groups across Europe.
Patients were not eligible for the study if they had any of the following:
(i) a history of prior or concomitant malignancy (except for curatively
treated non-melanoma skin cancer or carcinoma in situ of the cervix, or
other cancer for which the patient had been disease-free for 5 years);
(ii) active or uncontrolled infection; (iii) significant cardiovascular dis-
ease (uncontrolled hypertension, unstable angina, active congestive heart
failure, myocardial infarction within the previous year or uncontrolled
serious arrhythmia); (iv) pregnancy, lactation or refusal to use effective
contraception; (v) symptomatic brain metastases; (vi) evidence of peri-
pheral neuropathy; (vii) uncontrolled diabetes mellitus; or (viii) other
serious medical conditions that would impair the ability of the patient to
receive protocol treatment, including prior allergic reactions to drugs
containing Cremophor EL.
Ethics review
The institutional ethics committee of each participating institution
approved the study protocol. Written informed consent was obtained from
each patient prior to study entry. Patients were informed that although
cisplatin-based chemotherapy had been associated with survival benefit
compared with best supportive care, it was unknown whether there would
be a net or equal benefit from carboplatin instead of cisplatin when com-
bined with paclitaxel.
Randomisation and treatment
Randomisation was performed centrally by Bristol-Myers Squibb Inc.,
Waterloo, Belgium, using a dynamic balancing algorithm of the Pocock–
Simon type [21]. This procedure minimised imbalance in treatment
assignment with respect to the following parameters: centre, performance
status (ECOG 0–1 versus 2), disease stage (IIIB versus IV) and histology
(squamous cell versus non-squamous cell carcinoma).
Paclitaxel, cisplatin and carboplatin (Bristol-Myers Squibb Inc.,
Princeton, NJ, USA) were provided free of charge. Patients randomised to
the paclitaxel/cisplatin arm received on day 1 paclitaxel (200 mg/m2 as a
3-h intravenous infusion) followed by cisplatin (80 mg/m2 as a 30-min
intravenous infusion). Patients randomised to the paclitaxel/carboplatin
arm received on day 1 paclitaxel (200 mg/m2 as a 3-h intravenous
infusion) followed by carboplatin (AUC of 6 as a 30-min intravenous
infusion). The carboplatin dose was calculated using Calvert’s formula
[dose (mg) = area under the concentration time curve (glomerular filtration
rate + 25)]. Treatment was administered in 21-day cycles (Figure 1).
Paclitaxel was diluted in a minimum of 500 ml 5% dextrose or normal
saline. An in-line cellulose acetate filter of 0.22-µm pore size was used. In
both regimens, treatment continued at planned intervals of 3 weeks or
upon recovery from haematological and non-haematological toxic
effects. There were no dose escalations, and dose reduction was based on
toxic effects encountered in the previous treatment cycle. The response in
both arms was assessed every two cycles according to World Health
Organisation (WHO) criteria. Patients with progressive disease discon-
tinued chemotherapy. Patients with stable disease were treated for a
maximum of six cycles or until they had disease progression, developed
unacceptable drug toxicity not manageable by dosage modification or
withdrew their consent.
Patients who achieved a complete response or a partial response con-
tinued treatment for a total of 10 cycles or until disease progression.
Prevention of paclitaxel reactions consisted of dexamethasone (20 mg)
given orally on the evening before chemotherapy and again on the
morning of treatment, intravenous diphenhydramine (50 mg), and either
intravenous cimetidine (300 mg) or ranitidine (50 mg) given 30 min
before paclitaxel. Intravenous administration of dexamethasone (10 mg)
plus either ondansetron (24–32 mg) or granisetron (10 µg/kg) plus
lorazepam (1–2 mg) were suggested as components of the premedication
with antiemetic therapy. Oral dexamethasone was used prophylactically if
grade II or greater arthralgias/myalgias occurred.
Assessment of patients
The following parameters were assessed at baseline: medical history and
physical examination; ECG; blood counts (haemoglobin, granulocytes
and platelets); creatinine or EDTA clearance; chemistry (serum creatinine
and bilirubin); pregnancy testing for women of childbearing potential; and
tumour measurements. Chest X-ray and a computed tomography (CT)
scan of the chest and upper abdomen were required. Patients had repeated
evaluations at least every 6 weeks. Tumour response was assessed accord-
ing to WHO criteria (measurable disease; complete response, partial
response, stable disease and progressive disease). Tumours were re-
assessed during treatment with the same imaging method used to establish
baseline tumour measurement. Previously irradiated lesions were
excluded from evaluation for tumour response. Quality of life was
assessed with a validated, cancer-specific instrument that was self-admin-
istered at baseline and at the end of each cycle. The EORTC core quality-
of-life questionnaire (QLQ-C30) was used [22], together with a lung
cancer-specific quality-of-life module (QOL-LC13) [23]. These question-
naires measured global quality of life, five general cancer functional
domains (physical, role, cognitive, emotional and social functioning), and
20 symptoms (fatigue, nausea/vomiting, pain, chest pain, shoulder pain,
pain elsewhere, pain medication, pain medication help, dyspnea, cough,
insomnia, hemoptysis, sore mouth, dysphagia, constipation, diarrhoea,
peripheral neuropathy, alopecia, appetite and financial difficulties).
Statistical analysis
The primary goal of this study was to show non-inferiority in response
rate for paclitaxel/carboplatin compared with paclitaxel/cisplatin. The
target population size for the study was 568 patients. Under the paclitaxel/
cisplatin regimen, the expected response rate was ∼30%. The primary test
on response rate was a non-inferiority test with a null hypothesis that the
paclitaxel/carboplatin combination response rate was at least 10% worse.
Figure 1. Flow diagram including patient allocation and treatment 
schema.
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Therefore, using a significance level of 5%, statistically significant proof of
non-inferiority would be obtained if the lower limit of a two-sided
90% confidence interval (CI) of the difference in response rate between
paclitaxel/cisplatin and paclitaxel/carboplatin would be –10% or more.
Five hundred and twenty response-evaluable patients were needed to
obtain 80% power for this test, if the two regimens had the same true
response rate of 30%.
As this was a non-inferiority study, the most conservative dataset for
this primary analysis was the dataset of all response evaluable patients
[24]. This dataset was used for the primary analyses of response rate, sur-
vival and progression-free survival. The planned non-inferiority test of
survival (as well as progression-free survival) was to conclude non-inferi-
ority if the upper confidence level of the two-sided 90% CI of the hazard
ratio (paclitaxel/cisplatin versus paclitaxel/carboplatin) was 1.27 or less.
This confidence interval was obtained from a Cox regression stratified for
tumour stage, performance status and histology, with treatment as the sole
factor.
As a secondary analysis, all randomised patients were included in the
analysis of survival and progression-free survival, which was performed
strictly according to the intention-to-treat principle. The resulting
confidence intervals were interpreted in the context of a non-inferiority
test as well as a superiority test.
Progression-free survival was measured from the day of random-
isation to the time of progression or last follow-up. In a first definition of
progression-free survival, patients who received secondary therapy prior
to documented disease progression were censored at the time of the
secondary therapy. In a second definition, patients who received second-
ary radio- or chemotherapy were considered to have an event at that time.
The Cox proportional hazards regression model was used for
progression-free survival and survival, stratified by tumour stage, perform-
ance status and histology. The model included the following prognostic
variables: weight loss during the last 6 months prior to randomisation,
gender, prior radiotherapy and baseline haemoglobin. For each of the
time-to-event variables (survival, progression-free survival), Kaplan–
Meier estimates at 1 and 2 years were calculated per treatment arm with
their 95% CIs, as well as median estimates with their 95% CI.
Signs and symptoms of toxicity were reported according to their
severity in frequency tables. Toxicity was evaluated considering the worst
reported event per patient. For each toxicity, treatment arms were com-
pared using Fisher’s exact text for 2 × 2 tables for occurrence of any
toxicity and for occurrence of severe toxicity.
Quality-of-life treatment comparisons over time were assessed by
longitudinal analysis curves for the median change from baseline for the
global scale, for each of the five functional scales (physical, role, cognit-
ive, social, emotional), and for the 20 symptom scales with the use of the
Wei–Johnson test of stochastic ordering.
The final analysis was performed on the database locked on 2 Novem-
ber 1998. In addition to this, a survival update analysis was performed on
an updated database locked on 11 September 2001.
Results
Patient characteristics
Between April 1996 and July 1997, 618 patients were
randomised from 42 centres in 16 countries. Patient character-
istics for all randomised patients are listed in Table 1. Patient
characteristics at baseline were well balanced between the two
treatment arms. One hundred and seven patients—53 (17%) in
the paclitaxel/carboplatin arm and 54 (17%) in the paclitaxel/
cisplatin arm—had an ECOG performance status of 2. Among
the 618 patients randomised, a total of 616 had histologically
proven NSCLC (Table 2). One patient (enrolled in the paclit-
axel/cisplatin arm) had histiocytoma and one patient (enrolled
in the paclitaxel/cisplatin arm), originally thought to have
squamous cell carcinoma of the lung, was later found to have
squamous cell carcinoma of the larynx. Histology and tumour
stage were equally distributed among treatment arms. A total
of 369 (60%) patients had stage IV disease, 49 (8%) patients
had either local or metastatic disease and 198 (32%) patients
had stage IIIB disease. Two patients in the paclitaxel/cisplatin
arm had stage IIIA disease at baseline. Sixty-one patients
(10%) had received prior radiotherapy.
Presence of measurable disease was well balanced between
the two study arms. At baseline, 573 (93%) patients had bi-
dimensionally measurable disease while five (1%) patients had
unidimensionally measurable disease and 40 (6%) patients
were found, after review, to have non-measurable disease.
Chemotherapy administration
Of the 618 patients randomised, 10 (2%) never received any
study drug. A total of 1311 courses of paclitaxel/carboplatin
were administered to 306 patients, and 1321 courses of pac-
litaxel/cisplatin were administered to 302 patients (Table 2).
The median number of courses was four (range 1–10) in both
study arms. Twenty-six (8%) patients in the paclitaxel/
carboplatin arm received more than six courses of therapy
compared with 29 (10%) in the paclitaxel/cisplatin arm. One
hundred and fifty-six (51%) paclitaxel/carboplatin patients
and 75 (25%) paclitaxel/cisplatin patients had a dose reduc-
tion. In the paclitaxel/carboplatin arm, 71 patients had pacli-
taxel reduced and 144 patients had carboplatin reduced, while
in the paclitaxel/cisplatin arm, 47 patients had paclitaxel
reduced and 65 patients had cisplatin reduced. The median
cumulative dose of paclitaxel administered was similar in
both arms: 799 mg/m2 in the paclitaxel/carboplatin arm and
807 mg/m2 in the paclitaxel/cisplatin arm. The median pacli-
taxel dose intensity in both study arms was 65 mg/m2/week,
which is very close to the planned dose intensity of
66.7 mg/m2/week. In fact, >80% of patients in this study
received ≥90% of the scheduled paclitaxel dose intensity. The
median dose intensity of platinum agents in both arms was
also close to the planned dose intensity. In the paclitaxel/
carboplatin arm, the median dose intensity of carboplatin was
1.9 mg/ml·min/week, compared with the planned 2 mg/ml·
min/week. In the paclitaxel/cisplatin arm, the median dose
intensity of cisplatin was 26 mg/m2/week, very close to the
planned 26.7 mg/m2/week.
Response rate, progression-free survival and survival
Among the 618 patients randomised, 279 in the paclitaxel/
carboplatin arm and 284 in the paclitaxel/cisplatin arm had
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response-evaluable measurable disease (Table 3). In this
primary data set, the overall clinical response rate was 25%
(95% CI 20% to 31%) in the paclitaxel/carboplatin arm and
28% (95% CI 23% to 34%) in the paclitaxel/cisplatin arm. Of
note, four complete responses were observed in the paclitaxel/
carboplatin arm and two in the paclitaxel/cisplatin arm. The
two-sided 90% CI of the difference in response rate ranged
from –10% to 3.4%, indicating that paclitaxel/carboplatin is
statistically not inferior to paclitaxel/cisplatin. A classical
superiority test to compare response rates between the two
arms yielded a P value of 0.45. When all randomised patients
were considered (intention-to-treat dataset), the response rates
were 23% (70 of 309 patients) in the paclitaxel/carboplatin
arm and 26% (80 of 309 patients) in the paclitaxel/cisplatin arm.
Table 1. Patient characteristics (all randomised patients)
Paclitaxel/cisplatin 
(n = 309)
Paclitaxel/carboplatin 
(n = 309)
Total (n = 608)
Gender [n (%)]
Male 253 (82) 258 (83) 511 (83)
Female 56 (18) 51 (17) 107 (17)
Age (years)
Median 58 58 58
Range 29–78 27–76 27–78
<65 years [n (%)] 222 (72) 218 (71) 440 (71)
≥65 years [n (%)] 87 (28) 91 (29) 178 (29)
Weight loss [n (%)]
<5% 151 (49) 159 (51) 310 (50)
5% to 10% 62 (20) 53 (17) 115 (19)
>10% 47 (15) 50 (16) 97 (16)
Not reported 49 (16) 47 (15) 96 (16)
ECOG performance status [n (%)]
0 50 (16) 52 (17) 102 (17)
1 205 (66) 204 (66) 409 (66)
2 53 (17) 53 (17) 106 (17)
3 1 (<1) – 1 (<1)
Histology [n (%)]
Adenocarcinoma 139 (45) 145 (47) 284 (46)
Squamous cell carcinoma 117 (38) 115 (37) 232 (38)
Large cell carcinoma 29 (9) 31 (10) 60 (10)
Other 24 (8) 18 (6) 42 (7)
Tumour stage [n (%)]
IIIA 2 (1) 0 (0) 2 (<1)
IIIB 108 (35) 90 (29) 198 (32)
IV 178 (58) 191 (62) 369 (60)
Local relapse 8 (3) 9 (3) 17 (3)
Metastatic relapse 13 (4) 19 (6) 32 (5)
Prior radiotherapy [n (%)]
Yes 28 (9) 33 (11) 61 (10)
No 281 (91) 276 (89) 557 (90)
Tumour measurability [n (%)]
Bidimensionally measurable 288 (93) 285 (92) 573 (93)
Unidimensionally measurable 4 (1) 1 (<1) 5 (1)
Assessable 17 (6) 23 (7) 40 (6)
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At the time of the original analysis, 95% of patients in the
paclitaxel/carboplatin arm and 93% of patients in the pacli-
taxel/cisplatin arm had evidence of tumour progression or had
received secondary therapy prior to documentation of disease
progression. On the intention-to-treat dataset, median pro-
gression-free survival was 3 months (95% CI 2.7–3.9 months)
for the paclitaxel/carboplatin arm and 4.2 months (95% CI
3.3–4.4 months) for the paclitaxel/cisplatin arm (P = 0.035 by
log-rank test).
If the start of secondary therapy is regarded as an event,
on the intention-to-treat dataset, median progression-free
survival was 2.9 months (95% CI 2.7–3.5 months) in the pac-
litaxel/carboplatin arm and 3.3 months (95% CI 3–4 months)
in the paclitaxel/cisplatin arm (P = 0.36 by log-rank test)
(Figure 2).
More than half of the patients received at least one follow-
up therapy: 183 of 309 (59%) patients in the paclitaxel/carbo-
platin arm and 185 of 309 (60%) patients in the paclitaxel/
cisplatin arm (Table 4). Radiotherapy was the most frequent
type of secondary therapy. Overall, 44% of the patients
received subsequent radiotherapy after completion of the trial.
Chemotherapy was used in approximately one-quarter of the
patients. Twenty-four per cent of paclitaxel/carboplatin patients
and 23% of paclitaxel/cisplatin patients received at least one
secondary chemotherapy regimen. The most frequently used
second-line chemotherapeutic agents were gemcitabine,
vinorelbine, cisplatin, etoposide and mitomycin C (Table 5).
Overall, paclitaxel was re-administered in only five patients.
Of note, more patients in the paclitaxel/cisplatin arm than in
Table 2. Number of patients treated per cycle (all treated patients)
Paclitaxel/cisplatin 
(n = 302)
Paclitaxel/carboplatin 
(n = 306)
Course number 
[n (%)]
1 302 (100) 306 (100)
2 275 (91) 279 (91)
3 226 (75) 220 (72)
4 194 (64) 187 (61)
5 143 (47) 139 (45)
6 118 (39) 123 (40)
7 29 (10) 26 (8)
8 22 (7) 22 (7)
9 9 (3) 6 (2)
10 3 (1) 3 (1)
Total courses 1321 1311
Median number 
of courses
4 4
Range 1–10 1–10
Table 3. Response rates in response-evaluable patients with measurable 
tumour
Paclitaxel/cisplatin 
(n = 284) [n (%)]
Paclitaxel/carboplatin 
(n = 279) [n (%)]
Complete response 2 (1) 4 (1)
Partial response 78 (27) 66 (24)
Stable disease 123 (43) 112 (40)
Progressive disease 58 (20) 80 (29)
Early death, toxicity 23 (8) 17 (6)
Table 4. Follow-up therapies (all randomised patients)
aPatients may have more than one type of follow-up therapy.
bIncludes surgery, hormonotherapy, corticosteroid therapy and 
non-medically proven therapies.
Paclitaxel/
cisplatin [n (%)]
Paclitaxel/
carboplatin [n (%)]
Number of patients with 
any follow-up therapy
185 (60) 183 (59)
Radiotherapya 139 (45) 131 (42)
Chemotherapya 72 (23) 74 (24)
One regimen 58 67
Two regimens 10 6
Three regimens 4 0
Four regimens 0 1
Other therapiesa,b 31 (10) 26 (8)
Table 5. Second-line chemotherapy
Patients may have received more than one drug.
Paclitaxel/cisplatin 
(n = 72)
Paclitaxel/carboplatin 
(n = 74)
Gemcitabine 32 33
Vinorelbine 28 29
Cisplatin 12 15
Etoposide 13 7
Mitomycin C 7 4
Cyclophosphamide 4 6
5-Fluorouracil 5 5
Ifosfamide 7 2
Carboplatin 7 3
Methotrexate 1 4
Doxorubicin 1 3
Vindesine 1 3
Docetaxel 1 2
Vinblastine 0 3
Paclitaxel 4 1
Lomustine 0 3
Other agents 5 6
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the paclitaxel/carboplatin arm received salvage chemotherapy
and/or radiotherapy before disease progression. At the time of
this analysis, a total of 479 patients had died (81% of patients
in the paclitaxel/carboplatin arm and 74% of patients in the
paclitaxel/cisplatin arm). On the intention-to-treat dataset,
median survival was 8.5 months (95% CI 7.4–9.6 months) in
the paclitaxel/carboplatin arm and 9.8 months (95% CI 8.3–
11 months) in the paclitaxel/cisplatin arm. The Kaplan–Meier
estimates of survival rate at 1 year were 33% (95% CI 27% to
38%) in the paclitaxel/carboplatin arm and 38% (95% CI 33%
to 44%) in the paclitaxel/cisplatin arm.
At the time of the survival update (September 2001),
579 patients had died (95% of patients in the paclitaxel/
carboplatin arm and 92% of patients in the paclitaxel/cisplatin
arm). In the intention-to-treat analysis, median survival was
8.2 months (95% CI 7.4–9.6 months) in the paclitaxel/carbo-
platin arm and 9.8 months (95% CI 8.2–11 months) in the
paclitaxel/cisplatin arm (P = 0.019 by log-rank test) (Figure 3).
The stratified hazard ratio between treatment arms was 1.22
(90% CI 1.06–1.40).
Toxicity
All 608 patients who received at least one dose of therapy
were included in the toxicity analysis. This included
306 patients in the paclitaxel/carboplatin arm and 302 in the
paclitaxel/cisplatin arm. Haematological and non-haemato-
logical toxicity data are listed in Tables 6 and 7, respectively.
Figure 2. Kaplan–Meier curve of time to tumour progression of patients treated with paclitaxel/cisplatin and paclitaxel/carboplatin 
(intention-to-treat dataset).
Figure 3. Kaplan–Meier curve of survival of patients treated with paclitaxel/cisplatin and paclitaxel/carboplatin (intention-to-treat dataset, 
survival update September 2001).
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The combination of paclitaxel/carboplatin caused more severe
(grade III and IV) leukopenia and more severe thrombocyto-
penia than the combination of paclitaxel/cisplatin (Table 6).
Severe neutropenia and severe anaemia were reported at a
similar rate between the two study arms. Neutropenic fever
was reported in 6% of patients in the paclitaxel/carboplatin
arm and in 4% of patients in the paclitaxel/cisplatin arm
(P = 0.189). Severe infections were rare, occurring in 15 (5%)
patients in the paclitaxel/carboplatin arm and in 14 (5%)
patients in the paclitaxel/cisplatin arm (P = 1.000). The
combination of paclitaxel/cisplatin caused more nausea and
vomiting, diarrhoea and renal toxicity than the paclitaxel/
carboplatin combination (Table 7). There was no difference in
the incidence or severity between the two study arms in peri-
pheral neuropathy and myalgia/arthralgia. Hypersensitivity
reactions were reported in seven (2%) patients in the pacli-
taxel/carboplatin arm and in 10 (3%) patients in the paclitaxel/
cisplatin arm. Overall, three patients, all in the paclitaxel/
cisplatin arm, suffered from a severe hypersensitivity reac-
tion. Peripheral neuropathy, mostly grade I or II, was observed
in 59% of the patients in the paclitaxel/carboplatin arm and in
58% of the patients in the paclitaxel/cisplatin arm. Severe
events (grade III) were reported in 9% of patients in the pacli-
taxel/carboplatin arm and in 7% of patients in the paclitaxel/
cisplatin arm. Arthralgia/myalgia was reported in 62% of
patients in the paclitaxel/carboplatin arm and in 57% of
patients in the paclitaxel/cisplatin arm. These events were
generally mild to moderate in severity, and the incidence of
severe events was ∼10% in both arms. More patients in the
paclitaxel/cisplatin arm (38%) than in the paclitaxel/carbo-
platin arm (15%) developed renal toxicity. Severe events
occurred in three paclitaxel/carboplatin patients and in four
paclitaxel/cisplatin patients.
Quality-of-life analysis
Quality-of-life evaluation was performed in a large number
of patients and at a similar rate in both arms. At baseline,
258 (84%) patients in the paclitaxel/carboplatin arm and
256 (85%) patients in the paclitaxel/cisplatin arm completed
quality-of-life questionnaires. Compliance up to day 120 was
excellent, with two-thirds of the patients potentially available
for quality-of-life evaluation actually participating. From day
120, the number of patients decreased to <50% of all potential
patients. When comparing the changes from baseline over all
on-study periods (Table 8), significant differences between
the treatment arms were noted. Appetite loss was more severe
in the paclitaxel/cisplatin arm (P = 0.084); hemoptysis was
Table 6. Haematological toxicity (all treated patients)
aP <0.05.
Paclitaxel/
cisplatin 
(n = 302) (%)
Paclitaxel/
carboplatin 
(n = 306) (%)
Leukopenia
Any 73 74
Severe (grade III–IV) 16a 23
Neutropenia
Any 73 70
Severe (grade III–IV) 51 54
Thrombocytopenia
Any 13a 27
Severe (grade III–IV) 2a 8
Anaemia
Any 95 94
Severe (grade III–IV) 9 7
Febrile neutropenia 4 6
Infections
Any 16 20
Severe (grade III–IV) 5 5
Table 7. Non-haematological toxicities (all treated patients)
aP <0.05.
Paclitaxel/
cisplatin 
(n = 302) (%)
Paclitaxel/
carboplatin 
(n = 306) (%)
Hypersensitivity reaction
Any 3 2
Severe 1 0
Peripheral neuropathy
Any 58 59
Severe (grade III) 7 9
Arthralgia/myalgia
Any 57 62
Severe 9 8
Asthenia
Any 43 42
Severe 10 10
Ototoxicity
Any 4 3
Severe (grade III) 0 <1
Nausea/vomiting
Any 70a 49
Severe 14a 6
Diarrhoea
Any 19a 9
Severe 2 2
Renal toxicity
Any 38a 15
Severe (grade III) 1 1
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reported more frequently in the paclitaxel/carboplatin arm
(P = 0.048); pain and chest pain were also reported more
frequently in the paclitaxel/carboplatin arm (P = 0.058 and
0.046, respectively); and pain medication consumption was
higher in the paclitaxel/carboplatin arm (P = 0.054). Of note,
no significant differences in global health status or in the func-
tional scales, which are global indices of quality of life, were
noted between the two study arms.
Discussion
Between 1984 and 1985, the ECOG carried out a large five-
arm randomised trial in 743 metastatic NSCLC patients,
comparing iproplatin or carboplatin followed by MVP (mito-
mycin, vinblastine and cisplatin) at the time of progression,
doublets of vinblastine plus cisplatin, triplets of MVP and
MVP alternating with CAMP (cyclophosphamide, doxo-
rubicin, methotrexate and procarbazine). Carboplatin stood
out as having a significantly longer progression-free survival
(29 weeks; P = 0.01) and longer median survival (31.7 weeks).
The overall median survival for all patients was 25.4 weeks
[25]. Carboplatin has also been found to have survival benefit
in other tumours. For example, in a study of 1526 ovarian
cancer patients, no differences in survival were found between
those patients treated with CAP (cyclophosphamide, doxo-
rubicin and cisplatin) and those treated with single-agent
carboplatin [26].
This is the first large, randomised trial directly comparing
paclitaxel/carboplatin with paclitaxel/cisplatin in the treat-
ment of advanced NSCLC. The significantly superior survival
achieved with cisplatin differs from results reported in similar
US studies. In a recent four-arm ECOG trial [27], where 1207
patients were randomised to receive paclitaxel (as a 24-h intra-
venous infusion)/cisplatin, gemcitabine/cisplatin, docetaxel/
cisplatin, or paclitaxel (as a 3-h intravenous infusion)/carbo-
platin, the response rate for all 1155 evaluable patients was
19%, with a median survival of 7.9 months, a 1-year survival
rate of 33% and a 2-year survival rate of 11%. The response
rate and survival did not differ significantly between patients
receiving paclitaxel/cisplatin and those in any of the other
three arms [27]. On the other hand, a recent large international
randomised trial comparing docetaxel/carboplatin, docetaxel/
cisplatin and vinorelbine/cisplatin reported a significantly
superior median survival in the docetaxel/cisplatin arm
(10.9 months) [28], and a European randomised study also
reported a median survival of 10 months in the docetaxel/
cisplatin arm [29].
Differences between paclitaxel/cisplatin and paclitaxel/
carboplatin found in the present study are not due to an uneven
distribution of patient characteristics (Table 1) or to the
number of cycles received (Table 2). The only bias was that
dose reduction of carboplatin was necessary for 96 of 279
(34%) of evaluable patients; this reduction occurred mainly at
course 1, due to a miscalculation of AUC. The average AUC
for these 96 patients was 4.9.
The fact that there was no difference in the ECOG study
[27] between paclitaxel/carboplatin and paclitaxel/cisplatin
leads us to conclude that we must be cautious with the findings
of the present study. We can postulate that continuous infusion
of paclitaxel could modify the therapeutic efficacy of this com-
bination. In the prior ECOG study [15], the median survival
for the paclitaxel/cisplatin arm where paclitaxel was adminis-
tered by continuous infusion was 9.9 months compared with
7.6 months for the cisplatin/etoposide arm. The recommended
dose for further studies was paclitaxel 135 mg/m2 by 24-h con-
tinuous infusion plus cisplatin. In the study by Schiller et al.
[27], the control arm received this combination and found no
differences in comparison with paclitaxel 225 mg/m2 by 3-h
Table 8. EORTC QLQ-C30/LC-13 results: longitudinal comparison of 
differences from baseline (all treated patients)
aWei–Johnson stochastic ordering test.
P valuea in favour of: 
Paclitaxel/
cisplatin
Neither Paclitaxel/
carboplatin
Functional scales
Physical functioning 0.419
Role functioning 0.622
Emotional functioning 0.466
Cognitive functioning 0.588
Social functioning 0.384
Global health status 0.939
Symptoms scales
Nausea and vomiting 0.149
Trouble swallowing 0.866
Sore mouth 0.995
Constipation 0.468
Diarrhoea 0.252
Appetite loss 0.084
Fatigue 0.955
Insomnia 0.985
Hair loss 0.540
Peripheral neuropathy 0.792
Financial difficulties 0.313
Dyspnea 0.163
Cough 0.107
Haemoptysis 0.048
Pain 0.058
Pain in chest 0.046
Pain in shoulder 0.493
Pain elsewhere 0.488
Pain medication 0.054
Pain medication help 0.606
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infusion plus carboplatin AUC 6. This study is slightly differ-
ent from the present one, where patients received paclitaxel
200 mg/m2 by 3-h infusion plus carboplatin AUC 6. This point
should be taken into account in future studies and meta-
analyses.
This large European randomised study can contribute
greatly to resolving the longstanding debate on the superiority
of carboplatin- or cisplatin-based chemotherapy in lung
cancer. Given the longer median survival achieved with pac-
litaxel/cisplatin, its use can be recommended in the treatment
of patients with advanced and metastatic NSCLC. Paclitaxel/
carboplatin represents a viable alternative, with a similar
response rate, a good safety profile, manageable toxicity and
superior ease of administration.
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